135 related articles for article (PubMed ID: 37889103)
1. Canonical and Nuclear mTOR Specify Distinct Transcriptional Programs in Androgen-Dependent Prostate Cancer Cells.
Chen Y; Han L; Dufour CR; Alfonso A; Giguère V
Mol Cancer Res; 2024 Feb; 22(2):113-124. PubMed ID: 37889103
[TBL] [Abstract][Full Text] [Related]
2. Nuclear mTOR acts as a transcriptional integrator of the androgen signaling pathway in prostate cancer.
Audet-Walsh É; Dufour CR; Yee T; Zouanat FZ; Yan M; Kalloghlian G; Vernier M; Caron M; Bourque G; Scarlata E; Hamel L; Brimo F; Aprikian AG; Lapointe J; Chevalier S; Giguère V
Genes Dev; 2017 Jun; 31(12):1228-1242. PubMed ID: 28724614
[TBL] [Abstract][Full Text] [Related]
3. The mTOR chromatin-bound interactome in prostate cancer.
Dufour CR; Scholtes C; Yan M; Chen Y; Han L; Li T; Xia H; Deng Q; Vernier M; Giguère V
Cell Rep; 2022 Mar; 38(12):110534. PubMed ID: 35320709
[TBL] [Abstract][Full Text] [Related]
4. SREBF1 Activity Is Regulated by an AR/mTOR Nuclear Axis in Prostate Cancer.
Audet-Walsh É; Vernier M; Yee T; Laflamme C; Li S; Chen Y; Giguère V
Mol Cancer Res; 2018 Sep; 16(9):1396-1405. PubMed ID: 29784665
[TBL] [Abstract][Full Text] [Related]
5. Crosstalk between androgen and pro-inflammatory signaling remodels androgen receptor and NF-κB cistrome to reprogram the prostate cancer cell transcriptome.
Malinen M; Niskanen EA; Kaikkonen MU; Palvimo JJ
Nucleic Acids Res; 2017 Jan; 45(2):619-630. PubMed ID: 27672034
[TBL] [Abstract][Full Text] [Related]
6. Cooperativity and equilibrium with FOXA1 define the androgen receptor transcriptional program.
Jin HJ; Zhao JC; Wu L; Kim J; Yu J
Nat Commun; 2014 May; 5():3972. PubMed ID: 24875621
[TBL] [Abstract][Full Text] [Related]
7. Integration of regulatory networks by NKX3-1 promotes androgen-dependent prostate cancer survival.
Tan PY; Chang CW; Chng KR; Wansa KD; Sung WK; Cheung E
Mol Cell Biol; 2012 Jan; 32(2):399-414. PubMed ID: 22083957
[TBL] [Abstract][Full Text] [Related]
8. DNA-PK, Nuclear mTOR, and the Androgen Pathway in Prostate Cancer.
Giguère V
Trends Cancer; 2020 Apr; 6(4):337-347. PubMed ID: 32209447
[TBL] [Abstract][Full Text] [Related]
9. mTOR is a fine tuning molecule in CDK inhibitors-induced distinct cell death mechanisms via PI3K/AKT/mTOR signaling axis in prostate cancer cells.
Berrak O; Arisan ED; Obakan-Yerlikaya P; Coker-Gürkan A; Palavan-Unsal N
Apoptosis; 2016 Oct; 21(10):1158-78. PubMed ID: 27484210
[TBL] [Abstract][Full Text] [Related]
10. Darolutamide antagonizes androgen signaling by blocking enhancer and super-enhancer activation.
Baumgart SJ; Nevedomskaya E; Lesche R; Newman R; Mumberg D; Haendler B
Mol Oncol; 2020 Sep; 14(9):2022-2039. PubMed ID: 32333502
[TBL] [Abstract][Full Text] [Related]
11. Regulation of androgen receptor transcriptional activity by rapamycin in prostate cancer cell proliferation and survival.
Wang Y; Mikhailova M; Bose S; Pan CX; deVere White RW; Ghosh PM
Oncogene; 2008 Nov; 27(56):7106-17. PubMed ID: 18776922
[TBL] [Abstract][Full Text] [Related]
12. PI3K-AKT-mTOR pathway is dominant over androgen receptor signaling in prostate cancer cells.
Kaarbø M; Mikkelsen OL; Malerød L; Qu S; Lobert VH; Akgul G; Halvorsen T; Maelandsmo GM; Saatcioglu F
Cell Oncol; 2010; 32(1-2):11-27. PubMed ID: 20203370
[TBL] [Abstract][Full Text] [Related]
13. Dual role of FoxA1 in androgen receptor binding to chromatin, androgen signalling and prostate cancer.
Sahu B; Laakso M; Ovaska K; Mirtti T; Lundin J; Rannikko A; Sankila A; Turunen JP; Lundin M; Konsti J; Vesterinen T; Nordling S; Kallioniemi O; Hautaniemi S; Jänne OA
EMBO J; 2011 Sep; 30(19):3962-76. PubMed ID: 21915096
[TBL] [Abstract][Full Text] [Related]
14. Dissecting transcription of the 8q24-MYC locus in prostate cancer recognizes the equilibration between androgen receptor direct and indirect dual-functions.
Guo J; Wei Z; Jia T; Wang L; Nama N; Liang J; Liao X; Liu X; Gao Y; Liu X; Wang K; Fu B; Chen SS
J Transl Med; 2023 Oct; 21(1):716. PubMed ID: 37828515
[TBL] [Abstract][Full Text] [Related]
15. Androgen Receptor Enhances p27 Degradation in Prostate Cancer Cells through Rapid and Selective TORC2 Activation.
Fang Z; Zhang T; Dizeyi N; Chen S; Wang H; Swanson KD; Cai C; Balk SP; Yuan X
J Biol Chem; 2012 Jan; 287(3):2090-8. PubMed ID: 22139837
[TBL] [Abstract][Full Text] [Related]
16. Resveratrol regulates the PTEN/AKT pathway through androgen receptor-dependent and -independent mechanisms in prostate cancer cell lines.
Wang Y; Romigh T; He X; Orloff MS; Silverman RH; Heston WD; Eng C
Hum Mol Genet; 2010 Nov; 19(22):4319-29. PubMed ID: 20729295
[TBL] [Abstract][Full Text] [Related]
17. Skp2 regulates androgen receptor through ubiquitin-mediated degradation independent of Akt/mTOR pathways in prostate cancer.
Li B; Lu W; Yang Q; Yu X; Matusik RJ; Chen Z
Prostate; 2014 Apr; 74(4):421-32. PubMed ID: 24347472
[TBL] [Abstract][Full Text] [Related]
18. Androgen receptor and chemokine receptors 4 and 7 form a signaling axis to regulate CXCL12-dependent cellular motility.
Hsiao JJ; Ng BH; Smits MM; Wang J; Jasavala RJ; Martinez HD; Lee J; Alston JJ; Misonou H; Trimmer JS; Wright ME
BMC Cancer; 2015 Mar; 15():204. PubMed ID: 25884570
[TBL] [Abstract][Full Text] [Related]
19. Src promotes castration-recurrent prostate cancer through androgen receptor-dependent canonical and non-canonical transcriptional signatures.
Chattopadhyay I; Wang J; Qin M; Gao L; Holtz R; Vessella RL; Leach RW; Gelman IH
Oncotarget; 2017 Feb; 8(6):10324-10347. PubMed ID: 28055971
[TBL] [Abstract][Full Text] [Related]
20. FOXA1 regulates androgen receptor variant activity in models of castrate-resistant prostate cancer.
Jones D; Wade M; Nakjang S; Chaytor L; Grey J; Robson CN; Gaughan L
Oncotarget; 2015 Oct; 6(30):29782-94. PubMed ID: 26336819
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
